-
公开(公告)号：EP1766093B1
公开(公告)日：2011-06-15
申请号：EP05857759.4
申请日：2005-02-04
发明人： AMBROSINO, Donna , BABCOCK, Gregory, J. , BROERING, Theresa , GRAZIANO, Robert , HERNANDEZ, Hector, Javier , LOWY, Israel , MANDELL, Robert , MOLRINE, Deborah , THOMAS, William, D. , ZHANG, Hui-fen
IPC分类号： C07K16/12 , A61K39/395 , A61P31/04
CPC分类号： C07K16/1282 , A61K39/08 , A61K48/00 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N15/86 , G01N33/56911 , G01N2333/33 , Y10S424/809 , A61K2300/00
摘要： Antibodies that specifically bind to toxins of C.difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
-
2.发明公开ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF 有权抗氧化剂GEGEN CLOSTRIDIUM DIFFICILE-TOXINE UND IHRE VERWENDUNG
公开(公告)号：EP1766093A2
公开(公告)日：2007-03-28
申请号：EP05857759.4
申请日：2005-02-04
发明人： AMBROSINO, Donna , BABCOCK, Gregory, J. , BROERING, Theresa , GRAZIANO, Robert , HERNANDEZ, Hector, Javier , LOWY, Israel , MANDELL, Robert , MOLRINE, Deborah , THOMAS, William, D. , ZHANG, Hui-fen
IPC分类号： C12Q1/68
CPC分类号： C07K16/1282 , A61K39/08 , A61K48/00 , A61K2039/505 , A61K2039/507 , C07K2317/21 , C07K2317/24 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C12N15/86 , G01N33/56911 , G01N2333/33 , Y10S424/809 , A61K2300/00
摘要： Antibodies that specifically bind to toxins of C.difficile, antigen binding portions thereof, and methods of making and using the antibodies and antigen binding portions thereof are provided herein.
摘要翻译： 本文提供了特异性结合C.difficile毒素的抗体，其抗原结合部分，以及制备和使用抗体及其抗原结合部分的方法。
-
3.发明授权
公开(公告)号：EP1633785B1
公开(公告)日：2012-11-28
申请号：EP04809410.6
申请日：2004-05-21
申请人： Medarex, Inc.
CPC分类号： C07K16/1278 , A61K47/6835 , A61K51/1009 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
-
4.发明公开
公开(公告)号：EP1954311A2
公开(公告)日：2008-08-13
申请号：EP06846519.4
申请日：2006-12-07
申请人： MEDAREX, INC.
发明人： NICHOL, Geoffrey, M. , LOWY, Israel
IPC分类号： A61K39/395
CPC分类号： C07K16/2818 , A61K38/2013 , A61K39/00 , A61K39/39558 , A61K45/06 , A61K2039/505 , A61K2039/545 , C07K16/3053 , C07K2317/21
摘要： A disease or condition, such as cancer or an infectious disease, can be treated in a patient by administering a CTLA-4 antibody in an escalating dosage regimen until a partial or complete response is elicited in the patient or a pre¬ determined maximum dosage is reached.
摘要翻译： 可以通过在递增的剂量方案中施用CTLA-4抗体来在患者体内治疗疾病或病症，例如癌症或感染性疾病，直到在患者中引发部分或完全反应，或者预先确定的最大剂量为 到达。
-
5.发明公开TNF-ALPHA BLOCKER TREATMENT FOR ENTEROCOLITIS ASSOCIATED WITH IMMUNOSTIMULATORY THERAPEUTIC ANTIBODY THERAPY 审中-公开与相关的免疫刺激TNF-ALPHA-BLOCKER小肠结肠炎治疗的治疗性抗体治疗
公开(公告)号：EP1948214A2
公开(公告)日：2008-07-30
申请号：EP06827682.3
申请日：2006-11-08
申请人： MEDAREX, INC. , United States of America, as represented by the Secretary, Department of Health and Human Services
IPC分类号： A61K38/16 , A61K39/395 , C07K14/00 , C07K16/00
CPC分类号： A61K39/39558 , A61K39/3955 , A61K2039/507 , C07K16/241 , C07K16/2818
摘要： The present invention provides methods for treating adverse events related to immunotherapy. More specifically, the present invention provides methods for treating the enterocolitis associated with anti-CTLA-4 antibody immunotherapy.
-
6.发明公开
公开(公告)号：EP1633785A2
公开(公告)日：2006-03-15
申请号：EP04809410.6
申请日：2004-05-21
申请人： MEDAREX, INC.
IPC分类号： C07K16/00
CPC分类号： C07K16/1278 , A61K47/6835 , A61K51/1009 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要： Isolated human monoclonal antibodies which bind to Anthrax protective antigen 035 disclosed. The human antibodies can be produced in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. A1so disclosed are derivatives of the human antibodies (e.g., bispecific antibodies and immunoconjugates), pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.
-
7.发明公开SURROGATE THERAPEUTIC ENDPOINT FOR ANTI-CTLA-4 BASED IMMUNOTHERAPY OF DISEASE 审中-公开用于抗CTLA-4基因免疫治疗的治疗性终点
公开(公告)号：EP1639010A2
公开(公告)日：2006-03-29
申请号：EP04785793.3
申请日：2004-05-28
申请人： MEDAREX, INC.
发明人： LOWY, Israel , NICHOL, Geoffrey, M.
IPC分类号： C07K16/00 , A61K39/395
CPC分类号： G01N33/57492 , A61K2039/505 , C07K16/2818 , G01N2333/70521 , G01N2800/52
摘要： The present invention provides a method of treatment using human sequence antibodies against human CTLA-4. In particular, methods of treating cancer are provided.
摘要翻译： 本发明提供了使用针对人CTLA-4的人序列抗体的治疗方法。 具体而言，提供了治疗癌症的方法。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.017 秒)
